Teva Pharma (TEVA) Tops Q2 EPS by 6c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.61, $0.06 better than the analyst estimate of $0.55. Revenue for the quarter came in at $4.2 billion versus the consensus estimate of $4.06 billion.
GUIDANCE:
Teva Pharma sees FY2024 EPS of $2.30-$2.50, versus the consensus of $2.46. Teva Pharma sees FY2024 revenue of $16-16.4 billion, versus the consensus of $15.994 billion.
For earnings history and earnings-related data on Teva Pharma (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI-powered cyber threats light a fire under cybersecurity stocks
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
